Clinicopathologic Features of CD5-Positive Nodal Marginal Zone Lymphoma

Jaso, Jesse Manuel; Yin, C. Cameron; Wang, Sa A.; Miranda, Roberto N.; Jabcuga, Christine E.; Chen, Lei; Medeiros, L. Jeffrey

doi:10.1309/ajcpemvxes72duif

Cited by 26 publications

(13 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to the higher rates of nodal MZBCLs expressing CD5 (8.6%), 22 less than 1% of MALT lymphomas are positive for CD5. 23 Splenic MZBCLs exhibit positive CD5 expression in about 20% of the cases.…”

Section: 21mentioning

confidence: 70%

Diagnostic Algorithm of Common Mature B-Cell Lymphomas by Immunohistochemistry

Wang

Zu²

2017

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.-Different types of mature B-cell lymphomas, including plasma cell neoplasms, exhibit distinct immunohistochemical profiles, which enable them to be correctly diagnosed. However, except for rare examples of lymphoma-specific immunohistochemistry, such as cyclin D1 in mantle cell lymphoma and annexin A1 in hairy cell leukemia, immunohistochemical profiles of mature B-cell lymphomas overlap and lack specificity.Objectives.-To systemically review immunohistochemical features associated with commonly encountered mature B-cell lymphomas based on the presence or absence of CD5 and CD10; to review the immunophenotypic profile of plasma cells derived from plasma cell myelomas and B-cell lymphomas; and to review a group of rare, aggressive B-cell lymphomas with antigen expression features of plasma cells.Data Sources.-Published and PubMed-indexed English literature was reviewed.Conclusions.-Although the presence or absence of CD5 and CD10 expression should be included in the initial immunohistochemistry screening panel for mature B-cell lymphomas, appropriate and judicial use of other B-cell antigens is necessary to ensure correct diagnoses. Furthermore, although the status of CD5 and CD10 expression is associated with certain prototypes of B-cell lymphomas, their expression is not specific. Plasma cells from plasma cell neoplasias and B-cell lymphomas exhibit overlapping but relatively distinct immunophenotypes; thus, a panel of immunohistochemical markers (CD19, CD45, CD56, and CD117) can be employed for their proper identification. Lastly, CD138 staining results are almost always positive in a group of aggressive B-cell lymphomas with plasmablastic features, including plasmablastic plasma cell myeloma, plasmablastic lymphoma, and ALK-1 þ large B-cell lymphoma.

show abstract

Section: 21mentioning

confidence: 70%

Diagnostic Algorithm of Common Mature B-Cell Lymphomas by Immunohistochemistry

Wang

Zu²

2017

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…17,18 However, expression of CD5 also has been detected occasionally in other B-cell lymphomas including extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, nodal marginal zone lymphoma, splenic marginal zone lymphoma, lymphoplasmacytic lymphoma, follicular lymphoma, and diffuse large B-cell CD5+ follicular lymphoma lymphoma. 9,[19][20][21][22][23] In follicular lymphoma, CD5 expression has been associated with younger age, male predominance and grade 3 morphology. 4,6,8 More recently, Miyoshi et al 10 in Japan reported a series of 22 cases of CD5+ follicular lymphoma and found that patients with CD5+ follicular lymphoma showed a higher frequency of peripheral blood involvement, CD25 and MUM1 expression, and a lower frequency of t(14;18)(q32;q21; Table 3).…”

Section: Discussionmentioning

confidence: 99%

CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases

Liu

Zuo

et al. 2015

Modern Pathology

View full text Add to dashboard Cite

Follicular lymphoma is a low-grade B-cell lymphoma of germinal center B-cell origin that typically lacks CD5 expression. We describe the clinicopathologic features of 88 cases of CD5+ follicular lymphoma (53 men, 35 women; median age, 60 years; range, 31-86). Follicular lymphoma was diagnosed initially in lymph nodes in 66 and extranodal sites in 22 patients. Eighty-one patients had lymphadenopathy, 66 had more than one involved site, 46 had bone marrow involvement, and 7 had splenomegaly. Staging information was available for 84 patients: 52 stage IV, 18 stage III, 12 stage II, and 2 stage I. Sixty-one cases were grade 1 or 2 and 27 were grade 3. The median proliferation index (Ki-67) was 30%. CD5 expression was detected by flow cytometry in 69, immunohistochemistry in 8, and both methods in 11 cases. The presence of t(14;18)(q32;q21)/IGH-BCL2 or other BCL2 translocation was detected in 28/44 (64%) cases. A total of 38 (43%) patients also had diffuse large B-cell lymphoma, concurrent with (n = 20), subsequent to (n = 13), or developing before CD5+ follicular lymphoma (n = 5). All patients received chemotherapy; 12 also received stem-cell transplantation. With a median follow-up of 55 months (range, 0.5-207), 15 patients died, 46 were alive with disease, and 20 were in clinical remission. Compared with a matched group of patients with CD5− follicular lymphoma, patients with CD5+ follicular lymphoma more commonly had an International Prognostic Index 42 (35/80 vs 10/99, Po0.001), more often developed diffuse large B-cell lymphoma (38/88 vs 17/99; Po 0.001), and had a shorter median progression-free survival (44 vs 89 months, P = 0.0042). Higher Ki-67 and International Prognostic Index were identified as poor prognostic factors in both the groups. We conclude that CD5 expression in follicular lymphoma is associated with a higher International Prognostic Index, higher rate of transformation to diffuse large B-cell lymphoma, and shorter progression-free survival.

show abstract

“…For instance, CD23, which is is usually negative, may be actually present in about one third of cases [6]; this occurrence is very important because, if not properly recognized, may lead to diagnostic mistakes. In addition, CD5 expression may be seen roughly in 20% of NMZL; beside this possibility, it has been proven that CD5-positive NMZL display a more disseminated disease, although this occurrence does not impact on prognosis [6,23]. Cyclin D1 must be absent [6].…”

Section: Nmzl May Contain a Variable Amount Of Cells That Range From mentioning

confidence: 99%